AI Chatbot Use for Human Papillomavirus Vaccine Literacy in Japan

Importance Persistent misinformation and low confidence impede human papillomavirus (HPV) vaccine uptake in Japan. Artificial intelligence (AI)–driven conversational agents may provide scalable vaccine education, but randomized evidence for HPV vaccine communication remains limited. Objective To determine whether an AI-driven HPV vaccine chatbot improves caregiver HPV vaccine literacy compared with a government leaflet. Design, Setting, and Participants Parallel-group randomized clinical trial (RCT) conducted through a national research panel of female caregivers in Japan with unvaccinated daughters aged 12 to 18 years from November 30 to December 27, 2024, with 2-week follow-up. Interventions Participants were randomized 1:1 to an AI-driven HPV vaccine chatbot or standard government HPV vaccine leaflet. Main outcomes and measures The primary outcome was an HPV vaccine literacy, evaluated immediately after intervention to estimate immediate intervention efficacy and evaluated at 2-week follow-up to estimate durability. HPV vaccine literacy was measured using 7 factual questions about HPV and HPV vaccination; scores are shown on a 0 to 7 scale, with higher scores indicating more correct responses.The secondary outcome was decision to vaccinate at 2-week follow-up. Results Among 848 randomized participants, 704 of 841 (83.7%) were included in the immediate modified intention-to-treat (mITT) analysis (353 chatbot, 351 leaflet) and 477 of 841 (56.7%) in the mITT analysis at 2 weeks (237 chatbot, 240 leaflet). A total of 447 of 703 participants (63.6%) were aged 40 to 49 years and had college or university education (472 of 703 participants [67.1%]). Immediately after the intervention, analysis of covariance-adjusted literacy was higher with the chatbot (adjusted mean difference, 0.30 points on the 0 to 7 scale; 95% CI, 0.18-0.43 points; P < .001). At the 2-week durability assessment, mean (SD) literacy increased by 0.40 (1.21) with the chatbot vs 0.28 (1.13) points with the leaflet; adjusted literacy again favored the chatbot (adjusted mean difference, 0.30 points; 95% CI, 0.13-0.47; P < .001). At 2 weeks, caregivers’ vaccination decisions did not differ between groups (102 of 253 participants [40.3%] vs 103 of 260 participants [39.6%]; adjusted odds ratio, 0.74; 95% CI, 0.41 to 1.33; P = .31). Conclusions and Relevance In this RCT of female caregivers in Japan, an AI-driven HPV vaccine chatbot produced higher adjusted HPV vaccine literacy than a government leaflet immediately after intervention and at 2-week follow-up, without a measurable short-term effect on vaccination decision. Conversational AI may complement official materials and health care professional recommendations. Trial Registration ClinicalTrials.gov Identifier: NCT06702423

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-09-21
DOI
https://doi.org/10.1001/jamanetworkopen.2026.34696
Primary Topic
Vaccine Coverage and Hesitancy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

AI Chatbot Use for Human Papillomavirus Vaccine Literacy in Japan

Hana Tomoi, Kana Kobayashi, Ken Masuda, Heidi J. Larson et al.
JAMA Network Open
Vaccine Coverage and Hesitancy
article

AI Chatbot Use for Human Papillomavirus Vaccine Literacy in Japan

Hana Tomoi, Kana Kobayashi, Ken Masuda, Heidi J. Larson, Zhengdong Wu, Joseph T. Wu, Leesa Lin, Kathy Leung
article en

Abstract

Importance Persistent misinformation and low confidence impede human papillomavirus (HPV) vaccine uptake in Japan. Artificial intelligence (AI)–driven conversational agents may provide scalable vaccine education, but randomized evidence for HPV vaccine communication remains limited. Objective To determine whether an AI-driven HPV vaccine chatbot improves caregiver HPV vaccine literacy compared with a government leaflet. Design, Setting, and Participants Parallel-group randomized clinical trial (RCT) conducted through a national research panel of female caregivers in Japan with unvaccinated daughters aged 12 to 18 years from November 30 to December 27, 2024, with 2-week follow-up. Interventions Participants were randomized 1:1 to an AI-driven HPV vaccine chatbot or standard government HPV vaccine leaflet. Main outcomes and measures The primary outcome was an HPV vaccine literacy, evaluated immediately after intervention to estimate immediate intervention efficacy and evaluated at 2-week follow-up to estimate durability. HPV vaccine literacy was measured using 7 factual questions about HPV and HPV vaccination; scores are shown on a 0 to 7 scale, with higher scores indicating more correct responses.The secondary outcome was decision to vaccinate at 2-week follow-up. Results Among 848 randomized participants, 704 of 841 (83.7%) were included in the immediate modified intention-to-treat (mITT) analysis (353 chatbot, 351 leaflet) and 477 of 841 (56.7%) in the mITT analysis at 2 weeks (237 chatbot, 240 leaflet). A total of 447 of 703 participants (63.6%) were aged 40 to 49 years and had college or university education (472 of 703 participants [67.1%]). Immediately after the intervention, analysis of covariance-adjusted literacy was higher with the chatbot (adjusted mean difference, 0.30 points on the 0 to 7 scale; 95% CI, 0.18-0.43 points; P < .001). At the 2-week durability assessment, mean (SD) literacy increased by 0.40 (1.21) with the chatbot vs 0.28 (1.13) points with the leaflet; adjusted literacy again favored the chatbot (adjusted mean difference, 0.30 points; 95% CI, 0.13-0.47; P < .001). At 2 weeks, caregivers’ vaccination decisions did not differ between groups (102 of 253 participants [40.3%] vs 103 of 260 participants [39.6%]; adjusted odds ratio, 0.74; 95% CI, 0.41 to 1.33; P = .31). Conclusions and Relevance In this RCT of female caregivers in Japan, an AI-driven HPV vaccine chatbot produced higher adjusted HPV vaccine literacy than a government leaflet immediately after intervention and at 2-week follow-up, without a measurable short-term effect on vaccination decision. Conversational AI may complement official materials and health care professional recommendations. Trial Registration ClinicalTrials.gov Identifier: NCT06702423

JAMA Network OpenVol. 9(9)
Hong Kong University of Science and Technology (HK), University of Washington (US), Institute for Health Metrics and Evaluation (US), London School of Hygiene & Tropical Medicine (GB), Hong Kong Jockey Club (HK), University of Hong Kong - Shenzhen Hospital (CN), Nagasaki University (JP), University of Hong Kong (HK)
Quality Education
Openalex Percentile: Top 7%
Vaccine Coverage and Hesitancy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.